SGLT2 Inhibitors Market (2025 - 2033) Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Type 2 Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts

Market Segmentation

• SGLT2 Inhibitors Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Jardiance (empagliflozin)
  • Farxiga (dapagliflozin)
  • Invokana (canagliflozin)
  • Inpefa (sotagliflozin) 
  • Qtern (dapagliflozin/saxagliptin)
  • Other SGLT2 Inhibitors
• SGLT2 Inhibitors Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Type 2 Diabetes
  • Cardiovascular
  • Chronic Kidney Disease (CKD)
  • Others
• SGLT2 Inhibitors Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• SGLT2 Inhibitors Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • North America SGLT2 Inhibitors Market, By Drug
      • Jardiance (empagliflozin)
      • Farxiga (dapagliflozin)
      • Invokana (canagliflozin)
      • Inpefa (sotagliflozin) 
      • Qtern (dapagliflozin/saxagliptin)
      • Other SGLT2 Inhibitors
    • North America SGLT2 Inhibitors Market, By Indication
      • Type 2 Diabetes
      • Cardiovascular
      • Chronic Kidney Disease (CKD)
      • Others
    • North America SGLT2 Inhibitors Market, By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • U.S.
      • U.S. SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • U.S. SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • U.S. SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Canada
      • Canada SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Canada SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Canada SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Mexico
      • Mexico SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Mexico SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Mexico SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Europe
    • Europe SGLT2 Inhibitors Market, By Drug
      • Jardiance (empagliflozin)
      • Farxiga (dapagliflozin)
      • Invokana (canagliflozin)
      • Inpefa (sotagliflozin) 
      • Qtern (dapagliflozin/saxagliptin)
      • Other SGLT2 Inhibitors
    • Europe SGLT2 Inhibitors Market, By Indication
      • Type 2 Diabetes
      • Cardiovascular
      • Chronic Kidney Disease (CKD)
      • Others
    • Europe SGLT2 Inhibitors Market, By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Germany
      • Germany SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Germany SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Germany SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • UK
      • UK SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • UK SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • UK SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • France
      • France SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • France SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • France SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Italy
      • Italy SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Italy SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Italy SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Spain
      • Spain SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Spain SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Spain SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Denmark
      • Denmark SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Denmark SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Denmark SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Sweden
      • Sweden SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Sweden SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Sweden SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Norway
      • Norway SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Norway SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Norway SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Asia Pacific
    • Asia Pacific SGLT2 Inhibitors Market, By Drug
      • Jardiance (empagliflozin)
      • Farxiga (dapagliflozin)
      • Invokana (canagliflozin)
      • Inpefa (sotagliflozin) 
      • Qtern (dapagliflozin/saxagliptin)
      • Other SGLT2 Inhibitors
    • Asia Pacific SGLT2 Inhibitors Market, By Indication
      • Type 2 Diabetes
      • Cardiovascular
      • Chronic Kidney Disease (CKD)
      • Others
    • Asia Pacific SGLT2 Inhibitors Market, By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • China
      • China SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • China SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • China SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Japan
      • Japan SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Japan SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Japan SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • India
      • India SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • India SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • India SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • South Korea
      • South Korea SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • South Korea SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • South Korea SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Australia
      • Australia SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Australia SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Australia SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Thailand
      • Thailand SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Thailand SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Thailand SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Latin America
    • Latin America SGLT2 Inhibitors Market, By Drug
      • Jardiance (empagliflozin)
      • Farxiga (dapagliflozin)
      • Invokana (canagliflozin)
      • Inpefa (sotagliflozin) 
      • Qtern (dapagliflozin/saxagliptin)
      • Other SGLT2 Inhibitors
    • Latin America SGLT2 Inhibitors Market, By Indication
      • Type 2 Diabetes
      • Cardiovascular
      • Chronic Kidney Disease (CKD)
      • Others
    • Latin America SGLT2 Inhibitors Market, By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Brazil
      • Brazil SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Brazil SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Brazil SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Argentina
      • Argentina SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Argentina SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Argentina SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Middle East and Africa (MEA)
    • Middle East and Africa SGLT2 Inhibitors Market, By Drug
      • Jardiance (empagliflozin)
      • Farxiga (dapagliflozin)
      • Invokana (canagliflozin)
      • Inpefa (sotagliflozin) 
      • Qtern (dapagliflozin/saxagliptin)
      • Other SGLT2 Inhibitors
    • Middle East and Africa SGLT2 Inhibitors Market, By Indication
      • Type 2 Diabetes
      • Cardiovascular
      • Chronic Kidney Disease (CKD)
      • Others
    • Middle East and Africa SGLT2 Inhibitors Market, By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • South Africa
      • South Africa SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • South Africa SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • South Africa SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Saudi Arabia
      • Saudi Arabia SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Saudi Arabia SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Saudi Arabia SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Kuwait
      • Kuwait SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • Kuwait SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • Kuwait SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • UAE
      • UAE SGLT2 Inhibitors Market, By Drug
        • Jardiance (empagliflozin)
        • Farxiga (dapagliflozin)
        • Invokana (canagliflozin)
        • Inpefa (sotagliflozin) 
        • Qtern (dapagliflozin/saxagliptin)
        • Other SGLT2 Inhibitors
      • UAE SGLT2 Inhibitors Market, By Indication
        • Type 2 Diabetes
        • Cardiovascular
        • Chronic Kidney Disease (CKD)
        • Others
      • UAE SGLT2 Inhibitors Market, By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

Report content

Qualitative Analysis

• Industry overview
• Industry trends
• Market drivers and restraints
• Market size
• Growth prospects
• Porter’s analysis
• PESTEL analysis
• Key market opportunities prioritized
• Competitive landscape
  • Company overview
  • Financial performance
  • Product benchmarking
  • Latest strategic developments

Quantitative Analysis

• Market size, estimates, and forecast from 2021 to 2033
• Market estimates and forecast for product segments up to 2033
• Regional market size and forecast for product segments up to 2033
• Market estimates and forecast for application segments up to 2033
• Regional market size and forecast for application segments up to 2033
• Company financial performance